EP 2146962 A2 20100127 - NOVEL VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS
Title (en)
NOVEL VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS
Title (de)
NEUE VANILLOID-REZEPTOR LIGANDEN UND IHRE VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN
Title (fr)
NOUVEAUX LIGANDS DU RÉCEPTEUR VANILLOÏDE ET LEUR UTILISATION POUR LA FABRICATION DE MÉDICAMENTS
Publication
Application
Priority
- EP 2008002994 W 20080415
- DE 102007018151 A 20070416
Abstract (en)
[origin: CA2683910A1] The present invention relates to novel vanilloid receptor ligands of gene ral formula (I), a method for the production thereof, pharmaceuticals contai ning said compounds, and the use of said compounds for the production of pha rmaceuticals for treating migraines, depression, neurogenerative diseases, c ognitive diseases, anxiety disorders, epilepsy, coughs, diarrhoea, pruritus, inflammations, disorders of the cardiovascular system, eating disorders, me dication dependency, misuse of medication and in particular urinary incontin ence.
IPC 8 full level
C07D 213/64 (2006.01); A61K 31/44 (2006.01); A61K 31/4545 (2006.01); A61P 25/00 (2006.01); C07D 213/70 (2006.01); C07D 213/74 (2006.01)
CPC (source: EP KR US)
A61K 31/44 (2013.01 - KR); A61K 31/4402 (2013.01 - KR); A61P 1/00 (2017.12 - EP); A61P 1/04 (2017.12 - EP); A61P 1/12 (2017.12 - EP); A61P 1/14 (2017.12 - EP); A61P 3/04 (2017.12 - EP); A61P 3/12 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 9/12 (2017.12 - EP); A61P 11/00 (2017.12 - EP); A61P 11/02 (2017.12 - EP); A61P 11/04 (2017.12 - EP); A61P 11/06 (2017.12 - EP); A61P 11/08 (2017.12 - EP); A61P 13/02 (2017.12 - EP); A61P 13/10 (2017.12 - EP); A61P 15/10 (2017.12 - EP); A61P 17/00 (2017.12 - EP); A61P 17/02 (2017.12 - EP); A61P 17/04 (2017.12 - EP); A61P 17/06 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 19/10 (2017.12 - EP); A61P 23/02 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/04 (2017.12 - EP); A61P 25/06 (2017.12 - EP); A61P 25/08 (2017.12 - EP); A61P 25/14 (2017.12 - EP); A61P 25/16 (2017.12 - EP); A61P 25/18 (2017.12 - EP); A61P 25/22 (2017.12 - EP); A61P 25/24 (2017.12 - EP); A61P 25/26 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 25/30 (2017.12 - EP); A61P 25/32 (2017.12 - EP); A61P 25/36 (2017.12 - EP); A61P 27/02 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 29/02 (2017.12 - EP); A61P 31/12 (2017.12 - EP); A61P 31/22 (2017.12 - EP); A61P 37/08 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 213/64 (2013.01 - EP KR US); C07D 213/70 (2013.01 - EP US); C07D 213/74 (2013.01 - EP KR US)
Citation (search report)
See references of WO 2008125337A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
Designated extension state (EPC)
AL BA MK RS
DOCDB simple family (publication)
DE 102007018151 A1 20081023; AU 2008238245 A1 20081023; BR PI0810031 A2 20141014; CA 2683910 A1 20080416; CN 101687799 A 20100331; CN 101687799 B 20140723; CO 6220938 A2 20101119; EC SP099693 A 20091130; EP 2146962 A2 20100127; IL 201506 A0 20100531; JP 2010523726 A 20100715; JP 5557734 B2 20140723; KR 101497357 B1 20150302; KR 20100016594 A 20100212; MX 2009011139 A 20091030; NZ 580381 A 20120525; NZ 599254 A 20130726; RU 2009142024 A 20110527; RU 2487120 C2 20130710; US 2008262039 A1 20081023; US 2011184020 A1 20110728; US 8642775 B2 20140204; US 8791268 B2 20140729; WO 2008125337 A2 20081023; WO 2008125337 A3 20090226; ZA 200907096 B 20130327
DOCDB simple family (application)
DE 102007018151 A 20070416; AU 2008238245 A 20080415; BR PI0810031 A 20080415; CA 2683910 A 20080415; CN 200880020516 A 20080415; CO 09115659 A 20091016; EC SP099693 A 20091016; EP 08735252 A 20080415; EP 2008002994 W 20080415; IL 20150609 A 20091014; JP 2010503393 A 20080415; KR 20097023888 A 20080415; MX 2009011139 A 20080415; NZ 58038108 A 20080415; NZ 59925408 A 20080415; RU 2009142024 A 20080415; US 10319808 A 20080415; US 201113077452 A 20110331; ZA 200907096 A 20091012